Skip to main content

Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.

Publication ,  Journal Article
Zhou, KI; Lin, C; Neff, JL; Galal, A
Published in: BMJ Case Rep
May 17, 2023

The tyrosine kinase inhibitor dasatinib is approved for the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL). Patients on dasatinib can rarely develop a form of benign reversible reactive lymphadenopathy termed follicular lymphoid hyperplasia (FLH). Here, we describe a patient with Ph+ ALL who developed follicular lymphoma (FL) after prolonged treatment with dasatinib and who had complete remission of FL after discontinuation of dasatinib. This case suggests that dasatinib-associated FLH could be a premalignant condition that can transform into FL. Moreover, withdrawal of dasatinib may be sufficient for remission of dasatinib-associated FL.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMJ Case Rep

DOI

EISSN

1757-790X

Publication Date

May 17, 2023

Volume

16

Issue

5

Location

England

Related Subject Headings

  • Protein Kinase Inhibitors
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Philadelphia Chromosome
  • Lymphoma, Follicular
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Humans
  • Dasatinib
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhou, K. I., Lin, C., Neff, J. L., & Galal, A. (2023). Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia. BMJ Case Rep, 16(5). https://doi.org/10.1136/bcr-2022-252739
Zhou, Katherine Ismei, Chenyu Lin, Jadee Lee Neff, and Ahmed Galal. “Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.BMJ Case Rep 16, no. 5 (May 17, 2023). https://doi.org/10.1136/bcr-2022-252739.
Zhou KI, Lin C, Neff JL, Galal A. Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia. BMJ Case Rep. 2023 May 17;16(5).
Zhou, Katherine Ismei, et al. “Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia.BMJ Case Rep, vol. 16, no. 5, May 2023. Pubmed, doi:10.1136/bcr-2022-252739.
Zhou KI, Lin C, Neff JL, Galal A. Dasatinib-associated follicular lymphoma in a patient with B-cell acute lymphoblastic leukaemia. BMJ Case Rep. 2023 May 17;16(5).

Published In

BMJ Case Rep

DOI

EISSN

1757-790X

Publication Date

May 17, 2023

Volume

16

Issue

5

Location

England

Related Subject Headings

  • Protein Kinase Inhibitors
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Philadelphia Chromosome
  • Lymphoma, Follicular
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Humans
  • Dasatinib
  • 42 Health sciences
  • 32 Biomedical and clinical sciences